Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which featured weaker Healthcare sales and margins than we had anticipated. Lab’s first-quarter figures roughly aligned with our expectations. We judge organic growth should start improving in H2 2024e. We nudge down our estimates and valuation, though our long-term view of the equity story remains unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/